On 15 February, Vladimir Hrusa, General Manager of Sotio China, Zhang Yong, Chief Medical Officer of Sotio China, and Yang Ying, Government Affairs Manager of Eastern China visited Sanpower to discuss cooperation on tumour immunotherapy. Vice President of Sanpower Group Wang Tongyan received the guests.

Vladimir Hrusa visited the Sanpower Corporate Culture Showroom, Brookstone concept store and Ageing Service Command Centre. After acquiring a deeper understanding of Sanpower Group’s market position and development strategies, and Sanpower’s position and recent actions in the Broad Health industry, Vladimir Hrusa shared his astonishment for Sanpower’s development in the field.

During the discussion, Zhang Yong first introduced Sotio, a biotechnology company based in Prague, Czechia. Sotio focuses on treatment for cancers and autoimmune diseases and has a well-equipped cellular product production base. Its business covers Europe, China, the USA and Russia. Sotio is a subsidiary of PPF Group, the largest financial investment group in Central and Eastern Europe.

Vladimir Hrusa related that Sotio was very optimistic about the Chinese market and was actively developing business in China. At present, Sotio has established a cellular immunotherapy research laboratory in Beijing and has developed partnerships on clinical research with multiple top Chinese hospitals. Knowing that Sanpower Group had recently acquired Provenge, the world’s first and only FDA-approved cellular immunotherapy for prostate cancer treatment, Hrusa hoped to strengthen communication and cooperation with Sanpower Group and develop worldwide business with Sanpower. He also invited Sanpower to visit Sotio’s headquarters in Prague.

Wang Tongyan introduced Sanpower Group’s market position in the Broad Health industry and introduced the circumstances of Sanpower’s acquisition of Provenge. She said, “Sanpower’s “Broad Health” business covers cord blood storage, genetic testing and precision medicine. In the future, Sanpower will closely cooperate with medical institutions to extend the stem cell industrial chain from upstream storage to downstream clinical application. Sanpower is seeking partnerships in related field and hopes to cooperate with Sotio.” Both parties agreed to keep in contact and explore possibilities for future cooperation.